Trial Profile
A Phase I, Multicenter, Dose-Escalation Trial Evaluating Maximum-Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Adverse reactions
- Sponsors Athersys
- 06 Jan 2014 New trial record